Background: Poly (ADP-ribose) polymerase (PARP) inhibitors and histone deacetylase
(HDAC) inhibitors are new promising anticancer drugs. The aim of the present study was to …

Background Cancer is a multifactorial disease, which makes it difficult to cure. Since more
than one defective cellular component is often involved during oncogenesis, combination …

New chemotherapeutic agents are still required to further optimise treatment of leukemia
patients. Proteasome inhibition by bortezomib, PR-171 (carfilzomib) and NPI-0052 …

Several epigenetic changes have been recently implicated in the pathogenesis of several
human malignancies, including HL. This pathway is currently explored for cancer therapy …

Background. The majority of the clinical trials with poly (ADP-ribose) polymerase-1 (PARP-1)
inhibitors were conducted or are ongoing in patients with solid tumors, while trials with …

Resistance to chemotherapy is still a challenge for the treatment of acute myeloid leukemia.
Combination use of histone deacetylase inhibitors (HDACIs) and proteasome inhibitors may …

Summary Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and histone deacetylase
(HDAC) inhibitors have recently emerged as promising anticancer drugs. The aim of this …

Multidrug resistance mediated by the drug efflux protein, P-glycoprotein (P-gp), is one of the
principal mechanisms by which tumor cells escape the cell death induced by …

Background Combination therapy is a key strategy for minimizing drug resistance, a
common problem in cancer therapy. The microtubule-depolymerizing agent vincristine is …

Aim: Acetylation levels of histones are the result of the balance between histone
acetyltransfrases and histone deacetylases activities, which plays an important role in …